[{"from": "human", "value": "What can you tell me about this molecule? [C][C][C][C][=Branch2][Ring2][=Branch2][=N][N][=C][Branch2][Ring1][Ring1][C][=C][C][=Branch1][N][=C][Branch1][#Branch1][C][=C][Ring1][O][Ring1][=Branch1][O][C][O][C][C][=C][C][=Branch1][#Branch2][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][O][C][O][C][C]"}, {"from": "gpt", "value": "The molecule is a 2,3-benzodiazepine drug which is a benzodiazepine derivative. In contrast to classical 1,4-benzodiazepines, the compound does not bind to the benzodiazepine binding site of the gamma-aminobutyric acid receptor and its psychopharmacological profile differs from such compounds. Although Tofisopam is not approved for sale in North America, it is approved for use in various countries worldwide, including parts of Europe. The D-enantiomer ([dextofisopam]) is currently in phase II trials in the U.S. for the treatment of irritable bowel syndrome."}]